Home Tools
Log in
Cart

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No. Product name CAS No. Purity Chemical Structure
T36656 Anti-Spike-RBD Single Domain mAb 98%
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chun...
T9931 Meplazumab T9931 98%
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
T35390 Magrolimab (anti-CD47) 98%
T35395 Camrelizumab (anti-PD-1) 98%
T9927 Panitumumab 339177-26-3 98%
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
T39595 Disitamab vedotin 2136633-23-1 98%
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ...
T12706 Reslizumab 241473-69-8 98%
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T10497 Benralizumab 1044511-01-4 98%
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
T35389 Sarilumab (anti-IL-6Rα) 98%
T9923 Nimotuzumab 828933-51-3 98%
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T37535 Camrelizumab 1798286-48-2 98%
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhib...
T9928 Ranibizumab 347396-82-1 98%
Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T36646 Trastuzumab deruxtecan 1826843-81-5 98%
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of...
T36652 Anti-MERS-3A1 mAb 98%
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MER...
T9924 Obinutuzumab 949142-50-1 98%
Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
T38362 Guselkumab 1350289-85-8 98%
Guselkumab is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3....
T11126 Durvalumab 1428935-60-7 98%
Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
T9925 Ofatumumab 679818-59-8 98%
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
T35391 Vibostolimab (anti-TIGIT) 98%
T35394 Sintilimab (anti-PD-1) 98%
Anti-Spike-RBD Single Domain mAb
T36656
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chun...
meplazumab
T9931
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
Magrolimab (anti-CD47)
T35390
Camrelizumab (anti-PD-1)
T35395
Panitumumab
T9927
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
Disitamab vedotin
T39595
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated ...
Reslizumab
T12706
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
Benralizumab
T10497
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ...
Sarilumab (anti-IL-6Rα)
T35389
Nimotuzumab
T9923
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
Camrelizumab
T37535
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhib...
Ranibizumab
T9928
Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
Trastuzumab deruxtecan
T36646
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of...
Anti-MERS-3A1 mAb
T36652
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MER...
Obinutuzumab
T9924
Obinutuzumab GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
Guselkumab
T38362
Guselkumab is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3....
Durvalumab
T11126
Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
Ofatumumab
T9925
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation
Vibostolimab (anti-TIGIT)
T35391
Sintilimab (anti-PD-1)
T35394
1 2 3 4